Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 1:08 AM
Ignite Modification Date:
2025-12-25 @ 11:19 PM
NCT ID:
NCT03764293
Group ID:
EG000
Title:
Camrelizumab+Rivoceranib Arm
Description:
Camrelizumab+rivoceranib arm: Rivoceranib 250 mg orally, QD, within 30 minutes after a meal, continuously.
Camrelizumab 200 mg IV infusion, over 30 minutes, Q2W. The interval between two doses should not be less than 12 days.
Deaths Number Affected:
34
Deaths Number At Risk:
None
Serious Number Affected:
114
Serious Number At Risk:
272
Other Number Affected:
268
Other Number At Risk:
272
Study:
NCT03764293
Results Section:
NCT03764293
Adverse Events Module:
NCT03764293